MUMBAI, March 19, 2018 /PRNewswire/ --
Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced the launch of Nourkrin® Woman, a globally renowned, clinically-proven proteoglycan replacement formula, for normalizing hair growth cycle. Nourkrin® Woman will be exclusively marketed in India by Glenmark Pharmaceuticals under a licensing agreement with Denmark-headquartered firm Pharma Medico.
(Logo: http://mma.prnewswire.com/media/451507/PRNE_Glenmark_Logo.jpg )
(Photo: https://mma.prnewswire.com/media/655628/Rajesh_Kapur_Glenmark_Launches_Nourkrin_Woman.jpg )
Nourkrin® is a proven formula, based on more than 56 scientific studies and is recognized by leading regulatory agencies globally. Nourkrin® is the number one product in UK and Europe for hair loss management and is available in more than 40 countries worldwide. Nourkrin® Woman contains Marilex®, a unique and proprietary scientific formula, rich in specific proteoglycans (PG) essential for hair follicle development, which helps in normalizing, supporting and maintaining the Hair Growth Cycle.
Sujesh Vasudevan, President and Head - India, Middle East and Africa, Glenmark Pharmaceuticals, said, "Glenmark is proud to launch Nourkrin® Woman in India. Glenmark has been present in the field of Dermatology for over four decades bringing globally advanced therapies to Indian patients. The launch of Nourkrin® will enable millions of women in India to manage hair loss not by just preventing hair loss but by normalizing the hair growth cycle and tackling the problem at the follicular level."
Rajesh Kapur, Senior Vice President - Sales & Marketing, Glenmark Pharmaceuticals, said, "It is alarming to note that 60% women experience hair loss at some stage in their lives and in India there are more than 90 million women reported to have hair loss. With male and female hair loss patterns being different, Nourkrin® Woman is the first and exclusive product focusing on female hair loss problem through proteoglycan replacement."
Nourkrin® Woman is a core prescription product in India and will be promoted by Glenmark exclusively to dermatologists across the country. It will also be available at select retail chemists and healthcare portals.
According to Indian Journal of Clinical and Experimental Dermatology, 15.3% women in India reportedly suffer from hair loss which equates to about 90 million women reportedly suffering with hair loss problem.
Number of factors such as stress, pollution, certain medical disorders, childbirth, conditions caused by hormonal imbalances, use of certain drugs, nutritional deficiencies, and use of styling products disrupt the hair growth cycle and lead to hair loss in women. Nourkrin® Woman addresses the core issue of normalizing the hair growth cycle. Nourkrin® Woman, available as tablets, is an easy-to-use therapy compared to clinical procedures and hair sprays and creams. The tablets have to be consumed twice a day for six months. For more information on Nourkrin®, visit: https://nourkrin.com/india/ .
About Glenmark Dermatology:
Glenmark as an organization has always had a formidable presence in the field of dermatology with many pioneering formulations that were launched for the first time in India. Customers across the length and breadth of the country identify Glenmark - Dermatology as an innovation and quality led business unit having mega brands such as Candid, Candid B, Elovera, Scalpe, Onabet, Syntran to name just a few.
About Glenmark Pharmaceuticals Ltd:
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.
The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the U.S. and Western European markets. The API business sells its products in over 80 countries, including the U.S., various countries in the EU, South America and India. For more information, visit: http://www.glenmarkpharma.com/.
Media Contact: Isha Trivedi / Shibani Shah, email@example.com, +91-2240189999, Corporate Communications, Glenmark Pharmaceuticals
Subscribe to our Free Newsletters!
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...
Gardner or Gardner''s syndrome, also known as familial adenomatous polyposis (FAP), is an autosomal ...
Beetroot tea is a healthy beverage, which is extremely beneficial for high blood pressure, ...View All